Literature DB >> 3159337

Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography.

A Weber, D Chaffin, A Smith, K E Opheim.   

Abstract

We describe a reverse-phase high-pressure liquid chromatography method for the quantitation of a new quinoline carboxylic acid antimicrobial agent, ciprofloxacin (Bay o 9867). This assay utilizes the intrinsic fluorescence of ciprofloxacin for primary detection but employs UV absorption as a secondary detection system. Mobile phases contained methanol and phosphate buffer and used a common C18 mu Bondapak column. A single precipitation step of a 50-microliter specimen was the only sample preparation necessary. The assay is linear from 2,000 to 10 ng/ml and sensitive to 5 ng/ml. The mean recovery of ciprofloxacin from serum was 105.7%. The coefficient of variation was less than or equal to 3.1% for same-day precision and less than or equal to 6.3% for assay-to-assay precision. Because the assay requires only small specimen volumes and minimal sample preparation and because of its defined characteristics, this assay would be ideal for clinical trials and pharmacokinetics studies of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159337      PMCID: PMC180090          DOI: 10.1128/AAC.27.4.531

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

4.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

Authors:  G Panichi; A Pantosti; G P Testore
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  10 in total
  9 in total

1.  Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis.

Authors:  A Smith; A Weber; R Pandher; J Williams-Warren; M L Cohen; B Ramsey
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

2.  Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.

Authors:  A J Groeneveld; J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

3.  Pharmacokinetics of ciprofloxacin in cystic fibrosis.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; L Heggen; D Stempel; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population.

Authors:  Gabriel Marcelín-Jiménez; Alionka P Angeles; Luis Martínez-Rossier; Adolfo Fernández S
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis.

Authors:  M Magallanes; J Dijkstra; J Fierer
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

6.  Sucralfate significantly reduces ciprofloxacin concentrations in serum.

Authors:  J C Garrelts; P J Godley; J D Peterie; E H Gerlach; C C Yakshe
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

8.  Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.

Authors:  I Shalit; R B Greenwood; M I Marks; J A Pederson; D L Frederick
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.

Authors:  Nadine Lemaître; Isabelle Ricard; Elizabeth Pradel; Benoît Foligné; René Courcol; Michel Simonet; Florent Sebbane
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.